CooperCompanies missed Wall Street's revenue expectations in Q2 CY2026, with sales flat year on year at $1.07 billion against analyst estimates of $1.10 billion, a 2.9% miss. The medical device company's non-GAAP profit of $1.15 per share beat consensus of $1.12 by 2.7%, while operating margin rose to 20.8% from 16.6% a year earlier. Management lowered full-year revenue guidance to $4.24 billion at the midpoint from $4.30 billion, a 1.5% decrease, and cut full-year Adjusted EPS guidance to $4.53 at the midpoint, a 1.9% decrease. CEO Albert White attributed the shortfall to proactive U.S. channel inventory reductions in the vision segment and muted performance in China, and said the company concluded a strategic review by deciding to retain CooperSurgical after a disconnect between internal valuations and market offers. CFO Brian Andrews cautioned that near-term margin pressure is likely as commercial investments ramp up alongside foreign exchange and tariff headwinds, though CooperCompanies generated record free cash flow and repurchased $339 million in shares this quarter, with the board approving an additional $1 billion for buybacks.
The Cooper Companies, IncCooperCompanies missed Q2 revenue estimates and cut full-year revenue and EPS guidance, with margin pressure expected from investments, FX, and tariffs.
China Grand Pharmaceutical and Healthcare Holdings Ltd